Form 4: Neurocrine Biosciences Executive Receives Stock Grant
Insider Transaction (Form 4)
Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.
Summary
- Grant/award: acquired 6,275 Common Stock on September 11, 2026; holds 70,683 after (Direct).
- Tax/exercise-price withholding: disposed of 3,386 Common Stock at $156.22 ($528,961) on September 11, 2026; holds 67,297 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Eric Benevich — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Grant/award | Common Stock | 6,275 | — | — | 70,683 |
| 2026-09-11 | Tax/exercise-price withholding | Common Stock | 3,386 | $156 | $529.0K | 67,297 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Grant/award (6,275 shares) |
| 2026-09-11 | Tax/exercise-price withholding (3,386 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, neutral, Eric Benevich
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.